当前位置: X-MOL 学术Lymphat. Res. Biol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
EW-7197, a Transforming Growth Factor-Beta Type I Receptor Kinase Inhibitor, Ameliorates Acquired Lymphedema in a Mouse Tail Model.
Lymphatic Research and Biology ( IF 1.6 ) Pub Date : 2020-10-19 , DOI: 10.1089/lrb.2018.0070
Sung-Hwan Yoon 1, 2, 3 , Kun Yung Kim 4, 5 , Zhe Wang 6 , Jung-Hoon Park 1, 7 , Sang Mun Bae 8 , Sang-Yeob Kim 8, 9 , Ho-Young Song 1, 7 , Jae Yong Jeon 1, 3
Affiliation  

Background: Acquired lymphedema is a common consequence of cancer surgery. Fibrosis is one of the main causes of chronic lymphedema since it hinders lymphatic regeneration and this causes a significant decrease in lymphatic flow and accumulation of excessive protein-rich fluid. The transforming growth factor-β1 (TGF-β1) signaling pathway is known in a process of wound repair and fibrosis. In our study, the purpose was to evaluate the efficacy of EW-7197, a peroral TGF-β type I receptor kinase inhibitor, in treating acquired lymphedema.

中文翻译:

EW-7197 是一种转化生长因子 - β I 型受体激酶抑制剂,可改善小鼠尾部模型中的获得性淋巴水肿。

背景:获得性淋巴水肿是癌症手术的常见后果。纤维化是慢性淋巴水肿的主要原因之一,因为它会阻碍淋巴再生,这会导致淋巴流量显着减少和过多富含蛋白质的液体积聚。转化生长因子-β1 (TGF-β1) 信号通路在伤口修复和纤维化过程中是已知的。在我们的研究中,目的是评估 EW-7197(一种口服 TGF-β I 型受体激酶抑制剂)治疗获得性淋巴水肿的功效。
更新日期:2020-10-30
down
wechat
bug